Preclinical safety testing of DISC‐hGMCSF to support phase I clinical trials in cancer patients

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Gene Medicine

• Publication date

  2001-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/jgm.206PMID 11601759
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Guidance for Human Somatic Cell Therapy and Gene Therapy

  2001cited by this paper
• Guidance for human somatic cell therapy and gene therapy.

  2001cited by this paper
• Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.

  2000cited by this paper
• Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

  2000cited by this paper
• Repression of viral transcription during herpes simplex virus latency.

  2000cited by this paper
• Attenuated, Replication-Competent Herpes Simplex Virus Type 1 Mutant G207: Safety Evaluation in Mice

  2000cited by this paper
• Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

  2000cited by this paper
• Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse

  1999cited by this paper
• Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

  1999cited by this paper
• Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

  1999cited by this paper
• Disabled Infectious Single-Cycle Herpes Simplex Virus as an Oncolytic Vector for Immunotherapy of Colorectal Cancer

  1999cited by this paper
• Attenuated, Replication-Competent Herpes Simplex Virus Type 1 Mutant G207: Safety Evaluation of Intracerebral Injection in Nonhuman Primates

  1999cited by this paper
• Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.

  1998cited by this paper
• Mapping the In Vivo Distribution of Herpes Simplex Virions

  1998cited by this paper
• A Genetically Inactivated Herpes Simplex Virus Type 2 (HSV-2) Vaccine Provides Effective Protection against Primary and Recurrent HSV-2 Disease

  1997cited by this paper
• Selective Vulnerability of Mouse CNS Neurons to Latent Infection with a Neuroattenuated Herpes Simplex Virus-1

  1996cited by this paper
• Intranuclear foci containing low abundance herpes simplex virus latency-associated transcripts visualized by non-isotopic in situ hybridization.

  1993cited by this paper
• Granulocyte macrophage colony-stimulating factor

  1991cited by this paper
• Induction of encephalitis in SJL mice by intranasal infection with herpes simplex virus type 1: a possible model of herpes simplex encephalitis in humans.

  1991cited by this paper
• Quantitative polymerase chain reaction analysis of herpes simplex virus DNA in ganglia of mice infected with replication-incompetent mutants

  1990cited by this paper
• Intrinsic resistance to viral infection. Mouse macrophage restriction of herpes simplex virus replication.

  1988cited by this paper
• Persistent Infection with Herpes Simplex Virus Type 1 in an Ia Antigen‐Positive Murine Macrophage Cell Line

  1988cited by this paper
• An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs.

  1987cited by this paper
• Herpes simplex encephalitis: Immunohistological demonstration of spread of virus via olfactory pathways in mice☆

  1983cited by this paper
• Latent Herpes Simplex Virus in Spinal Ganglia of Mice

  1971cited by this paper

• Field-based safety evaluation of rVHSV-GΔTM in aquaculture and verification of vaccine efficacy through freeze-dried prototyping in olive flounder.

  2025cites this paper
• Late gene expression–deficient cytomegalovirus vectors elicit conventional T cells that do not protect against SIV

  2023cites this paper
• Advances in Alpha Herpes Viruses Vaccines for Human

  2023cites this paper
• Nanocarrier vaccines for SARS-CoV-2

  2021cites this paper
• Herpes Simplex Viruses Whose Replication Can Be Deliberately Controlled as Candidate Vaccines

  2020cites this paper
• Immunization by Replication-Competent Controlled Herpesvirus Vectors

  2018cites this paper
• Detection of replication-defective hepatitis A virus based on the correlation between real-time polymerase chain reaction and ELISA in situ results

  2013cites this paper
• Replication-Defective Herpes Simplex Virus Mutant Strains as Genital Herpes Vaccines and Vaccine Vectors

  2011cites this paper
• Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein.

  2010cites this paper
• Rationalizing the development of live attenuated virus vaccines

  2010cites this paper
• Author ' s personal copy

  2008cites this paper
• Replication-defective viruses as vaccines and vaccine vectors.

  2006influential citation
• Viral vaccines for cancer immunotherapy.

  2006cites this paper
• Gene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development

  2004cites this paper
• Safety and biodistribution studies of an HSV multigene vector following intracranial delivery to non-human primates

  2004cites this paper
• Herpes simplex virus type 1 amplicons and their hybrid virus partners, EBV, AAV, and retrovirus.

  2004cites this paper
• Cancer gene therapy and immunotherapy.

  2003cites this paper
• Cancer immunotherapy: an embarrassment of riches?

  2003cites this paper
• Characterization of secreted and intracellular forms of a truncated hepatitis C virus E2 protein expressed by a recombinant herpes simplex virus.

  2003cites this paper
• Preclinical evaluation of DISC‐GMCSF for the treatment of breast carcinoma

  2003cites this paper
• Gene therapy for pancreatic cancer.

  2002cites this paper